Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.54 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.52 |
| ▸ | APP | P05067 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA5A | P35218 | 1/20 | 0.48 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.48 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23346078 | 0.76 | NOTUM (0.60) | KDM1AAMY1ACA9CA2CA12 | |
| SCHEMBL27428598 | 0.76 | GLS (0.42) | KDM1AAMY1A | |
| SCHEMBL27423393 | 0.76 | GLS (0.42) | KDM1AAMY1A | |
| SCHEMBL28167508 | 0.75 | CA9 (0.57) | KDM1AAMY1ACA9CA2CA12 | |
| SCHEMBL31753264 | 0.72 | KDM1A (0.53) | KDM1AAMY1ACA9CA2CA12 | |
| SCHEMBL27423365 | 0.71 | P2RX7 (0.61) | KDM1AAPPCA9CA2CA12 | |
| SCHEMBL17454486 | 0.71 | BCHE (0.53) | CA9CA2CA12CA1CA5A | |
| SCHEMBL15578485 | 0.71 | STIM1 (0.54) | CA9CA2CA5ANOTUMBCHE | |
| SCHEMBL27430548 | 0.71 | CA1 (0.58) | CA9CA2CA12CA1RXRA | |
| SCHEMBL16238217 | 0.71 | MAOA (0.54) | NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208923-A1 | SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION | JNANA THERAPEUTICS INC. | 2024-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240208923-A1 | SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION | SLC18A2, SLC6A19, SLC1A1 | KDM1A 4524/4885AMY1A 4553/4885APP 2312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.